What is the most recent earnings date for RLMD stock?
RELMADA THERAPEUTICS INC (RLMD) last reported earnings on 3/19/2026.
NASDAQ:RLMD • US75955J4022
Past quarterly earnings results for RELMADA THERAPEUTICS INC (RLMD), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.29 | -0.14 | -103.08% | 53.23% | - | - | ||
| Q3 2025 | -0.30 | -0.12 | -153.55% | 58.33% | - | - | ||
| Q2 2025 | -0.30 | -0.26 | -17.65% | 49.15% | - | - | ||
| Q1 2025 | -0.58 | -0.32 | -83.43% | 19.44% | - | - | ||
| Q4 2024 | -0.62 | -0.71 | 12.98% | 26.19% | - | - | ||
| Q3 2024 | -0.72 | -0.65 | -10.12% | 1.37% | - | - | ||
| Q2 2024 | -0.59 | -0.84 | 30.01% | 29.76% | - | - | ||
| Q1 2024 | -0.72 | -0.87 | 16.90% | 17.24% | - | - | ||
| Q4 2023 | -0.84 | -0.85 | 0.78% | 40.43% | - | - | ||
| Q3 2023 | -0.73 | -0.93 | 21.61% | 44.27% | - | - | ||
| Q2 2023 | -0.84 | -0.91 | 8.17% | 36.84% | - | - | ||
| Q1 2023 | -0.87 | -0.91 | 4.08% | 37.86% | - | - | ||
| Q4 2022 | -1.41 | -1.35 | -4.12% | 21.67% | - | - | ||
| Q3 2022 | -1.31 | -1.48 | 11.40% | 46.31% | - | - | ||
| Q2 2022 | -1.33 | -1.30 | -2.42% | 14.74% | - | - | ||
| Q1 2022 | -1.40 | -1.29 | -8.45% | -4.48% | - | - | ||
| Q4 2021 | -1.80 | -1.87 | 3.57% | -37.40% | - | - | ||
| Q3 2021 | -2.44 | -1.63 | -49.82% | -132.38% | - | - | ||
| Q2 2021 | -1.56 | -1.50 | -3.81% | -113.70% | - | - | ||
| Q1 2021 | -1.34 | -1.42 | 5.78% | -212.79% | - | - | ||
| Q4 2020 | -1.31 | -1.18 | -10.84% | - | - | - | ||
| Q3 2020 | -1.05 | -0.88 | -19.01% | - | - | - | ||
| Q2 2020 | -0.73 | -0.60 | -22.34% | - | - | - | ||
| Q1 2020 | -0.43 | - | - | - | - |
Notes
RELMADA THERAPEUTICS INC (RLMD) last reported earnings on 3/19/2026.
RELMADA THERAPEUTICS INC (RLMD) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, RELMADA THERAPEUTICS INC (RLMD) has beaten EPS estimates in 0 out of 4 releases.